Search for: "In Re IT Group, Inc., Co." Results 181 - 200 of 2,420
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Nov 2014, 5:52 am
Parke, Davis & Co., 256 F.3d 1013, 1021 (10th Cir. 2001) (wrong to “construe [a treater’s] ‘heeding’ an adequate warning to mean [s/he] would have given the warning”) (applying Oklahoma law); In re Diet Drug Litigation, 895 A.2d 480, 490-91 (N.J. [read post]
However, in virtually all of these cases, the private fact was shared within a group that had a very specific relationship with the plaintiff, such as co-workers or participants in an in vitro fertilization program.3 We are not aware of any case holding that facts disclosed to dozens or hundreds of people who do not form a cohesive group are private from a private employer, especially when that group includes management-level employees of the employer who is the… [read post]
24 Sep 2009, 5:09 am
BOC Group PLC, 2001 WL 477237, at *5 (N.D. [read post]
28 Sep 2009, 1:31 am
BOC Group PLC, 2001 WL 477237, at *5 (N.D. [read post]
28 Sep 2009, 1:31 am
BOC Group PLC, 2001 WL 477237, at *5 (N.D. [read post]
28 Sep 2009, 1:31 am
BOC Group PLC, 2001 WL 477237, at *5 (N.D. [read post]
1 Sep 2007, 7:24 am
He participated in an investor group that executed a leveraged buyout of CSG, with infoUSA investing $500,000 in a CSG acquisition fund;  Reznicek who serves as the non-executive chairman of CSG Systems (a company founded by Haddix, another director, and in which InfoUSA had invested);  Kahn, the former Chairman and CEO of One source Information Services, a company acquired by InfoUSA in 2004; and Stryker, the… [read post]
7 Oct 2013, 5:47 am by Lawrence B. Ebert
Teleflex Inc., 550 U.S. 398, 418 (2007)(quoting In re Kahn, 441 F.3d 977, 988 (Fed. [read post]
7 Nov 2008, 12:59 pm
We will be following the multidistrict litigation In re: Chiquita Brands International, Inc., pending in the Southern District of Florida. [read post]
22 Aug 2012, 7:51 am by arester
Cell Therapeutics, Inc., resulting in $10.5 million settlement arising from unlawful off-label promotion to induce government purchases of the cancer drug Trisenox. [read post]